Under the terms of the deal, Cognizant will offer centralized statistical programming, statistical analysis, medical writing, and document publishing services, covering clinical data reporting, from case report forms to clinical study reports.
Cognizant will leverage its Web 2.0-based platform, Cognizant 2.0, to support knowledge sharing and collaboration there by helping in the management of clinical studies across different countries besides delivering productivity benefits to AstraZeneca.
AstraZeneca will benefit by increasing its operational efficiency, reducing cycle times, and optimizing costs.
The pharmaceutical giant will continue to own and manage major scientific and medical activities associated with the design of clinical trial programs, and the interpretation of data from Cognizant.